Ouabain (G Strophanthin)

A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.

Also Known As:

Networked: 1859 relevant articles (60 outcomes, 155 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hamlyn, John M: 21 articles (03/2014 - 02/2002)
2.	Manunta, Paolo: 20 articles (01/2015 - 01/2005)
3.	Bianchi, Giuseppe: 20 articles (11/2014 - 08/2004)
4.	Lingrel, Jerry B: 14 articles (04/2012 - 02/2005)
5.	Blaustein, Mordecai P: 13 articles (03/2014 - 11/2005)
6.	Ferrari, Patrizia: 12 articles (11/2014 - 08/2004)
7.	Liu, Lijun: 11 articles (03/2015 - 04/2003)
8.	Quevedo, João: 10 articles (08/2015 - 12/2009)
9.	Valvassori, Samira S: 10 articles (08/2015 - 12/2009)
10.	Messaggio, Elisabetta: 10 articles (01/2015 - 09/2005)

Related Diseases

1.	Ventricular Tachycardia 04/01/1976 - "The dose of ouabain necessary to produce ventricular tachycardia and death in 1-to 4-week-old rabbits was significantly greater than that required in older animals. " 03/01/1976 - "In 13 dogs the efficacy of the drug against ouabain-induced ventricular tachycardia (VT) was studied. " 09/01/2005 - "Further extract reversed ouabain-induced persistent ventricular tachycardia and restored sinus rhythm in a dose-dependent manner. " 12/01/1993 - "In contrast, this drug abolished ventricular tachycardia induced by ouabain toxicity (n = 10, 40 micrograms.kg-1 bolus followed by 0.076 microgram.kg-1.min-1 for 1 h, then 20 micrograms.kg-1 bolus, intravenously). " 07/01/1993 - "It also made the preparations develop stable ventricular tachycardia at an ouabain blood concentration of 0.246 +/- 0.007 microM, which was not significantly different from the concentration at which early arrhythmias were noted in the other series. "
2.	Hypertension (High Blood Pressure) 01/01/1993 - "The ouabain-induced changes were significantly greater in essential hypertension than in normotensive subjects. " 09/03/1983 - "In two thirds of the untreated hypertensive and several of the normotensive subjects with a family history of hypertension the potency of the digitalis-like compound, as measured by its interference with ouabain binding, was significantly greater than in the controls. " 02/01/1996 - "Among Caucasian patients with essential hypertension, a large fraction have elevated circulating levels of endogenous ouabain, possibly caused by an inherited or acquired renal defect in clearance of this steroid. " 03/01/2014 - "This study reports the critical role of endogenous ouabain in volume-dependent hypertension. " 01/01/2014 - "This study was designed to help settle this controversy through the use of telemetric monitoring of arterial blood pressure and to elucidate the ouabain-induced alterations that could either promote or prevent hypertension. "
3.	Ischemia 08/01/1988 - "In contrast, ouabain treatment resulted in a marked decrease in diastolic chamber distensibility during ischemia; this change was not completely reversible during the 10-minute reperfusion period. " 03/01/2010 - "A short (4 minutes) administration of a subinotropic dose of ouabain (100 nM) followed by an 8-minute washout before 30 minutes of global ischemia and 120 minutes of reperfusion resulted in protection against cell death, as evidenced by a significant decrease in infarct size. " 02/01/1996 - "A delayed adaptation produced a late appearing, prolonged protection against consequences of ischemia, such as early morphological changes, early and late postocclusion and reperfusion arrhythmias due to coronary artery occlusion or ouabain intoxication. " 03/01/2015 - "In Langendorff-perfused mouse hearts, OPC was initiated by 4 min of ouabain 10 μM and IPC was triggered by 4 cycles of 5 min ischemia and reperfusion prior to 40 min of global ischemia and 30 min of reperfusion. " 01/01/2013 - "OPC, induced by a 4-min exposure to 10 μM ouabain that ended 8 min before the beginning of ischemia, increased cell viability in a PKCε-dependent manner. "
4.	Cardiac Arrhythmias (Arrythmia) 01/01/2008 - "CPA significantly increased the time of onset of arrhythmia (toxicity) induced by ouabain (1.2 muM) when it was administered 10 min before ouabain was added in organ bath. " 12/28/2006 - "In the ventricle strip, NCX(IF) ( approximately 10 U/ml) results in rapid, complete and stable inhibition of ouabain-induced arrhythmias (the inhibition of arrhythmia is not followed by revival of irregular contractions). " 02/01/2002 - "Cardiac arrhythmias in an animal model for ouabain-induced toxicity were associated with neural autonomic dysfunction. " 11/01/2000 - "To determine the effective plasma levels of CPU-86017 which could suppress the cardiac arrhythmias induced by i.v. ouabain in guinea pigs. " 11/01/2000 - "Plasma CPU-86017 concentrations regarding suppression of ouabain-induced cardiac arrhythmias and decrease of heart rate in guinea pigs."
5.	Ventricular Fibrillation 03/01/1998 - "Ouabain was administered until ventricular fibrillation was induced. " 04/01/1996 - "Ouabain-induced ventricular fibrillation occurred at 18 +/- 5 and 12 +/- 3 min (P < 0.05) in control and AM 92016-(1 mg kg-1) treated guinea-pigs, respectively. " 03/01/1992 - "Ventricular fibrillation (VF) developed in three of the eight hearts in Group I within 10-13 mins after the addition of ouabain. " 01/01/1992 - "The threshold dose of ouabain necessary to induce ventricular fibrillation is decreased in sensitized guinea-pigs signalizing an enhanced arrhythmogenicity. " 11/01/1980 - "Although ventricular arrhythmias did occur before the increase in circulating CA, preinjection CA levels were significantly higher in animals presenting ventricular fibrillation, suggesting that a high background adrenergic tone facilitates the production of ventricular arrhythmias by ouabain. "

Related Drugs and Biologics

1.	Adenosine Triphosphatases (ATPase)
2.	Aconitine
3.	Sodium-Potassium-Exchanging ATPase (Sodium, Potassium ATPase)
4.	Furosemide (Lasix)
5.	Lidocaine (Xylocaine)
6.	Flunarizine
7.	Quinidine (Chinidin)
8.	Dopamine (Intropin)
9.	Epoprostenol (Prostacyclin)
10.	Hydralazine (Apresoline)

Related Therapies and Procedures

1.	Ligation
2.	Intravenous Infusions
3.	Denervation
4.	Oral Administration
5.	Catheters